Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

Ross L. Levine, Animesh Pardanani, Ayalew Tefferi, D. Gary Gilliland

Research output: Contribution to journalReview articlepeer-review

406 Scopus citations


The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors. The genetic cause of these diseases was not known until 2005, when several independent groups demonstrated that most patients with PV, ET and PMF acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new molecular targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.

Original languageEnglish (US)
Pages (from-to)673-683
Number of pages11
JournalNature Reviews Cancer
Issue number9
StatePublished - Sep 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders'. Together they form a unique fingerprint.

Cite this